摘要:金秋九月,硕果飘香。2025年9月15日,第61届欧洲糖尿病研究协会年会(EASD 2025)于奥地利维也纳金色大厅盛大启幕。这场糖尿病研究领域的全球顶级盛会,每年吸引数千医学工作者,涵盖基础研究、临床诊疗、技术创新与护理等多维度,以专题讨论、口头报告等形式,
金秋九月,硕果飘香。2025年9月15日,第61届欧洲糖尿病研究协会年会(EASD 2025)于奥地利维也纳金色大厅盛大启幕。这场糖尿病研究领域的全球顶级盛会,每年吸引数千医学工作者,涵盖基础研究、临床诊疗、技术创新与护理等多维度,以专题讨论、口头报告等形式,搭建学术交流广阔平台。今年,EASD年会再度设立“延迟公布摘要(LBA)”专场,聚焦7场口头报告与6场简短讨论,96项研究精准捕捉糖尿病研究前沿热点。其中,中国19项研究入选,接收率接近20%,为全球糖尿病研究注入东方智慧与活力!现整理如下,以飨读者。
LBA 01.Precision phenotyping of type 2 diabetes in Chinese populations using a variational autoencoder-informed tree model
基于变分自编码器特征筛选的中国人群T2DM的精准分型模型
LBA 05.Age-specific associations between blood pressure and cardiovascular disease, renal disease, and death among people with type 2 diabetes: a population-based cohort study
不同年龄段2型糖尿病患者血压水平与心血管疾病、肾病及死亡的关联:基于人群的队列研究
LBA 10.Mid-pregnancy lipidomic signatures identify metabolic subtypes associated with divergent pregnancy outcomes
孕中期脂质组学特征揭示与不同妊娠结局相关的代谢亚型
LBA 26.Multi-omics profiling reveals microbiota, metabolite and immunological heterogeneity of age-related endotypes in type 1 diabetes
多组学分析揭示1型糖尿病年龄相关内型的微生物组、代谢组、脂质组及免疫学异质性
LBA 38.Voluntary wheel running exercise orchestrates hepatic Lac-Phe and facilitates energy metabolism by activating oxidative phosphorylation
自主轮跑运动通过协调肝脏中乳酸苯丙氨酸的生成、激活氧化磷酸化,促进能量代谢
LBA 39.Efficacy and safety of a novel oral small molecule GLP-1RA (HRS-7535) in Chinese patients with type 2 diabetes inadequately controlled by metformin and SGLT2 inhibitor
一种新型口服小分子 GLP-1RA(HRS-7535)在中国2型糖尿病患者(使用二甲双胍和SGLT2i控制不佳者)中的疗效和安全性研究
LBA 41.Dorzagliatin enhances GLP-1 secretion by restoring the function of intestinal L-cells
多格列艾汀通过恢复肠道L细胞功能促进GLP-1的分泌
LBA 52.GenSci156, a potent bi-specific antibody targeting ActRIIA/B and GIPR for obesity treatment without causing muscle loss
GenSci156:靶向ActRIIA/B和GIPR的双特异性抗体,用于肥胖治疗且无肌肉流失
LBA 57.Once-monthly zovaglutide (ZT002) for the treatment of overweight or obesity in adults: a phase 2 study
每月一次的佐维格鲁肽(ZT002)治疗成人超重或肥胖症:II期临床试验.
LBA 59. Mazdutide inhibits ASK1 phosphorylation and SLC7A11-GPX4 ferroptosis axis to improve rat uric acid nephropathy
玛仕度肽抑制ASK1磷酸化和SLC7A11-GPX4铁死亡轴,改善大鼠尿酸肾病
LBA 61. Lac-Phe enhances hepatic energy homeostasis via pparα-mediated fatty acid oxidation
Lac-Phe通过pparα介导的脂肪酸氧化增强肝脏能量稳态
LBA 62.Exercise-induced rewiring of hepatic tryptophan metabolism promotes energy homeostasis via MFN1-dependent mitochondrial fusion
运动诱导的肝脏色氨酸代谢重布线通过MFN1依赖的线粒体融合促进能量稳态
LBA 64.CDK4/6 inhibition promotes Brown Adipose Tissue (BAT)
CDK4/6抑制通过线粒体代谢重塑促进棕色脂肪组织(BAT)产热
LBA 76. Diagnostic glycaemic thresholds for diabetes based on biopsy-confirmed diabetic kidney disease: comparative analysis with retinopathy-derived criteria
基于活检确诊糖尿病肾病的糖尿病诊断血糖阈值:与视网膜病变衍生标准的比较分析
LBA 80.The mechanism of MMP-7 mediating RAAS activation associated with diabetic kidney injury through syndecan-1 pathway
MMP-7通过syndecan-1通路介导RAAS激活与糖尿病肾损伤的机制
LBA 84. Zovaglutide (ZT002), a novel ultra long-acting GLP-1 receptor agonist improves memory function and prevents degenerative processes in Alzheimer’s disease animal models
佐维格鲁肽(ZT002),新型超长效GLP-1RA,能够改善阿尔茨海默病动物模型的记忆功能,并阻止其退化过程
LBA 85.ZT006, a novel oral GLP-1 receptor agonist improves memory function, reduces brain insulin resistance and neuroinflammation in Alzheimer’s disease animal models
新型口服GLP-1RA(ZT006)改善阿尔茨海默病动物模型的记忆功能,降低脑胰岛素抵抗和神经炎症
LBA 88.F.prausnitzii-derived butyrate induces remission of type 1 diabetes through CPT1A-mediated TIGIT+ Treg metabolic reprogramming
源自F.prausnitzii的丁酸盐通过CPT1A介导的TIGIT+Treg 细胞代谢重编程,缓解1型糖尿病
LBA 93.A simple clinical risk score identifies Chinese patients with severe insulin deficiency diabetes subtypes and adverse outcomes: a prospective cluster analysis
简单临床风险评分鉴别具有严重胰岛素缺乏糖尿病亚型及不良结局相关联的中国患者:基于前瞻性聚类研究
结语:
中国在EASD 2025上的杰出表现,不仅彰显了其在糖尿病研究领域的深厚实力,更预示着未来在精准医疗、个性化治疗、创新药物研发及基础机制探索等方面的巨大潜力。随着科技的不断进步,中国有望在糖尿病诊疗技术上实现重大突破,为全球糖尿病患者带来福音。同时,中国研究的持续深入和国际合作的加强,将推动全球糖尿病防治事业向前发展,使更多患者受益于中国智慧和方案。
以上信息来源EASD官网查询
来源:国际糖尿病